The oral doses used in the DSS-induced colitis model were selected on the basis of the in vitro STAT3 inhibitory IC50 values and preliminary pharmacokinetic profiles of HCB-5300 and HCB-5400, which indicated that 25 mg/kg and 12.5 mg/kg, respectively, achieved plasma exposures expected to exceed the cellular IC50 over the dosing interval (Supplementary Figure S1). The gene discussed is STAT3; the disease is colitis.